HIV-2 viral tropism influences CD4 1 T cell count regardless of viral load

BACKGROUND HIV-2 infection is characterized by low plasma viraemia and slower progression to AIDS in comparison with HIV-1 infection. However, antiretroviral therapy in patients with HIV-2 is less effective and often fails to provide optimal CD4 recovery. METHODS We examined viral tropism in persons with HIV-2 infection enrolled in the HIV-2 Spanish cohort. Viral tropism was estimated based on V3 sequences obtained from plasma RNA and/or proviral DNA. RESULTS From a total of 279 individuals with HIV-2 infection recorded in the Spanish national register, 58 V3 sequences belonging to 42 individuals were evaluated. X4 viruses were recognized in 14 patients (33%). Patients with X4 viruses had lower median CD4+ cell counts than patients with R5 viruses [130 (17-210) versus 359 (180-470) cells/mm(3); P = 0.007]. This was true even considering only the subset of 19 patients on antiretroviral therapy [94 (16-147) versus 184 (43-368) cells/mm(3); P = 0.041]. In multivariate analysis, significant differences in CD4+ cell counts between patients with X4 and R5 viruses remained after adjusting for age, gender, antiretroviral therapy and viral load. CONCLUSIONS The presence of X4-tropic viruses in HIV-2 infection is associated with low CD4+ cell counts, regardless of antiretroviral treatment. Along with CD4+ cell counts, viral tropism testing may assist decisions about when to initiate antiretroviral therapy in HIV-2-infected individuals.

[1]  Soham Gupta,et al.  High concordance of genotypic coreceptor prediction in plasma-viral RNA and proviral DNA of HIV-1 subtype C: implications for use of whole blood DNA in resource-limited settings. , 2013, The Journal of antimicrobial chemotherapy.

[2]  C. Charpentier,et al.  Transmitted drug resistance in French HIV-2-infected patients , 2013, AIDS.

[3]  C. Charpentier,et al.  Concordance between HIV-2 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA , 2013, AIDS.

[4]  C. Charpentier,et al.  Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool. , 2012, The Journal of infectious diseases.

[5]  C. Charpentier,et al.  In Vitro Phenotypic Susceptibility of HIV-2 Clinical Isolates to CCR5 Inhibitors , 2011, Antimicrobial Agents and Chemotherapy.

[6]  E. Poveda,et al.  Impact of baseline HIV-1 tropism on viral response and CD4 cell count gains in HIV-infected patients receiving first-line antiretroviral therapy. , 2011, The Journal of infectious diseases.

[7]  M. Wainberg,et al.  Antiretroviral Drug Resistance in Human Immunodeficiency Virus Type 2 , 2009, Antimicrobial Agents and Chemotherapy.

[8]  F. Dabis,et al.  Title : First year lymphocyte T CD 4 + response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration . Running head : CD 4 response and HIV type in West Africa , 2009 .

[9]  F. Brun-Vézinet,et al.  HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. , 2008, The Journal of antimicrobial chemotherapy.

[10]  B. Gazzard,et al.  The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  S. Rowland-Jones,et al.  Tenets of protection from progression to AIDS: lessons from the immune responses to HIV-2 infection , 2008, Expert review of vaccines.

[12]  F. Brun-Vézinet,et al.  In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors , 2008, Antimicrobial Agents and Chemotherapy.

[13]  E. Poveda,et al.  Prevalence of X4 tropic HIV‐1 variants in patients with differences in disease stage and exposure to antiretroviral therapy , 2007, Journal of medical virology.

[14]  J. Garson,et al.  Development and evaluation of a real-time RT-PCR assay for quantification of cell-free human immunodeficiency virus type 2 using a Brome Mosaic Virus internal control. , 2006, Journal of virological methods.

[15]  E. Poveda,et al.  HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors , 2006, AIDS.

[16]  E. Poveda,et al.  Enfuvirtide, the first fusion inhibitor to treat HIV infection. , 2005, AIDS reviews.

[17]  N. Taveira,et al.  Evidence for negative selective pressure in HIV-2 evolution in vivo. , 2005, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[18]  W. Heneine,et al.  Susceptibility of HIV-2, Siv and Shiv to Various Anti-HIV-1 Compounds: Implications for Treatment and Postexposure Prophylaxis , 2004, Antiviral therapy.

[19]  R. Doms,et al.  Human immunodeficiency virus type 2. , 2002, Journal of General Virology.

[20]  R. D’Aquila,et al.  Antiretroviral drug resistance in HIV-1 , 1999, Current infectious disease reports.

[21]  H. Whittle,et al.  Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. , 1998, Journal of human virology.